Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Trillium Therapeutics Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Trillium Therapeutics Inc. - Product Pipeline Review - 2014', provides an overview of the Trillium Therapeutics Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Trillium Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Trillium Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Trillium Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Trillium Therapeutics Inc.'s pipeline products Reasons to buy - Evaluate Trillium Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Trillium Therapeutics Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Trillium Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Trillium Therapeutics Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Trillium Therapeutics Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Trillium Therapeutics Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Trillium Therapeutics Inc. Snapshot 5 Trillium Therapeutics Inc. Overview 5 Key Information 5 Key Facts 5 Trillium Therapeutics Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Trillium Therapeutics Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Trillium Therapeutics Inc. - Pipeline Products Glance 10 Trillium Therapeutics Inc. - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Trillium Therapeutics Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Trillium Therapeutics Inc. - Drug Profiles 12 tigecycline 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 TTI-1612 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 CD200-Specific Monoclonal Antibody 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 TTI-621 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 TTI-622 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Trillium Therapeutics Inc. - Pipeline Analysis 17 Trillium Therapeutics Inc. - Pipeline Products by Target 17 Trillium Therapeutics Inc. - Pipeline Products by Route of Administration 18 Trillium Therapeutics Inc. - Pipeline Products by Molecule Type 19 Trillium Therapeutics Inc. - Pipeline Products by Mechanism of Action 20 Trillium Therapeutics Inc. - Recent Pipeline Updates 21 Trillium Therapeutics Inc. - Dormant Projects 24 Trillium Therapeutics Inc. - Discontinued Pipeline Products 25 Discontinued Pipeline Product Profiles 25 (human chorionic gonadotropin-Beta + epoeitin alfa) 25 Trillium Therapeutics Inc. - Locations And Subsidiaries 26 Head Office 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 28 Disclaimer 28
List of Tables Trillium Therapeutics Inc., Key Information 5 Trillium Therapeutics Inc., Key Facts 5 Trillium Therapeutics Inc. - Pipeline by Indication, 2014 7 Trillium Therapeutics Inc. - Pipeline by Stage of Development, 2014 8 Trillium Therapeutics Inc. - Monotherapy Products in Pipeline, 2014 9 Trillium Therapeutics Inc. - Phase I, 2014 10 Trillium Therapeutics Inc. - Preclinical, 2014 11 Trillium Therapeutics Inc. - Pipeline by Target, 2014 17 Trillium Therapeutics Inc. - Pipeline by Route of Administration, 2014 18 Trillium Therapeutics Inc. - Pipeline by Molecule Type, 2014 19 Trillium Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2014 20 Trillium Therapeutics Inc. - Recent Pipeline Updates, 2014 21 Trillium Therapeutics Inc. - Dormant Developmental Projects,2014 24 Trillium Therapeutics Inc. - Discontinued Pipeline Products, 2014 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.